|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
However, across PSA cutoffs, MRI-TBx detected more prostate cancer than TRUS-Bx at PSA levels of 2.5 to <4 (29.5% vs. 56.6%; P < .001).
|
30415878 |
2019 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The AUC-ROCs distinguishing nonprostate cancer vs prostate cancer, nonprostate cancer plus low Gleason Grade Group and low volume vs remaining prostate cancer with a higher Gleason Grade group or a higher volume on the PHI (Prostate Health Index) were significantly superior to the AUC-ROCs of prostate specific antigen and free-to-total prostate specific antigen.
|
31430244 |
2020 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We aimed to emphasize how useful PSMA PET/CT findings can be while trying to restage prostate cancer after radical prostatectomy in the presence of low prostate-specific antigen values.
|
28319496 |
2017 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In a previous population-based study on 3369 European men with self-reported prostate cancer (PCa), it was shown that androgen receptor (AR) haplotype designated H2 was associated with high levels of serum PSA (prostate-specific antigen) concentration, and, at the same time, with low risk for PCa.
|
28176139 |
2017 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In summary, the differences among the PCa/BPH/healthy control groups with respect to miR-320a/-b/-c levels in conjunction with higher levels in patients without a PSA relapse than in those with a relapse suggest the diagnostic potential of these miRNA-320 family members in PCa patients.
|
29535815 |
2018 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
A nomogram predicting PC at TB was constructed using the Prostate Imaging Reporting and Data System version 2.0, age, PSA density and biopsy technique, showing improved clinical risk prediction against a threshold probability of 10% with a c-index of 0.83.
|
29685613 |
2018 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
A 75-year-old man who received a diagnosis of RCC in 2006 and prostate cancer in 2009 presented with elevated prostate-specific antigen levels (0.7 ng/mL) following prostatectomy.
|
28033223 |
2017 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Endogenous miR-588 levels were quantified by qRT-PCR in both prostate-specific antigen (PSA)-negative and PSA-positive PCa cell lines, as well as human PCa tumors.
|
28980707 |
2017 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Biochemical control, distant metastasis-free survival (DMFS), prostate cancer-specific survival (PCSS), and overall survival (OS) were compared between those who achieved a nadir PSA ≤0.5 ng/mL with those who did not via Kaplan-Meier analysis.
|
30112266 |
2018 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We evaluated the ability of phi and PCA3 to identify prostate cancer (PCa) at initial prostate biopsy in men with total PSA range of 2-10 ng/ml.
|
23861782 |
2013 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Cell proliferation, prostate-specific antigen, gene transfer, and Western blot assays were used to study the effects of sodium selenite and methylseleninic acid on IL-6 mediated AR action on an AR expressing human prostate cancer cell line, LNCaP.
|
17346688 |
2007 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Effects of the MTHFR C677T polymorphism on prostate specific antigen and prostate cancer.
|
22296369 |
2011 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The detection range and sensitivity of the prepared sensor are good enough to diagnose the early stage of prostate cancer (> 4ng/mL of PSA).
|
29172142 |
2018 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Prostate cancer is usually diagnosed after the finding of a suspicious serum prostate-specific antigen level or digital rectal examination.
|
28473080 |
2017 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The widespread use of prostate-specific antigen (PSA) resulted in stage migration of prostate cancer where androgen deprivation therapy (ADT) is administered for biochemical recurrence in patients following primary treatment.
|
30015690 |
2018 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action.
|
17440964 |
2007 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Moreover, the PCA3 score was significantly higher in men with high-grade prostate intraepithelial neoplasia (HGPIN) versus those without HGPIN, clinical stage T2 versus T1, Gleason score >or=7 versus <7, and "significant" versus "indolent" (clinical stage T1c, PSA density [PSAD] <0.15ng/ml, Gleason score in biopsy <or=6, and percent positive cores <or=33%) pCA.
|
18602209 |
2008 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
In a secondary analysis of a contemporary U.S. cohort, suspicious digital rectal examination and abnormal prostate specific antigen on routine screening were independently associated with clinically significant prostate cancer and prostate cancer specific mortality.
|
27569432 |
2017 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Expression of miR-301a could be a valuable adjunct tool for stratifying patients with elevated prostate-specific antigen, as well as those diagnosed with CaP.
|
30195463 |
2018 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Remarkably, GOAT significantly outperformed PSA in the diagnosis of PCa and significant PCa in patients with PSA levels ranging from 3 to 10 ng/mL (the so-called PSA grey-zone).
|
31766715 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Cases had incident histologically-confirmed prostate cancer and controls were men with normal digital rectal examination and prostate-specific antigen (PSA) < 4 μg/L or free: total PSA > 0.15 obtained from the same clinic.
|
28864928 |
2017 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Two of the classical kallikrein genes KLK3 and KLK2 on 19q13.4 are plausible candidates in prostate cancer susceptibility.
|
17593395 |
2007 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Positive predictive value analysis of prostate cancer was increased from 40% to 87.5% by integrating patient PSA blood levels with miR-21 and miR-141 profiles.
|
21345070 |
2011 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We report a significant difference in the distribution of prostate specific antigen (PSA) levels skewed towards higher PSA levels in the PCa cases (83.0% present with a PSA ≥ 20 µg/L; median PSA = 98.8 µg/L) relative to men with no detectable PCa (18.5% present with a PSA ≥ 20 µg/L; median PSA = 9.1 µg/L).
|
24723425 |
2014 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
MRI-guided transperineal prostate biopsy was performed on 78 patients who had presented to our hospital with a prostate-specific antigen level >4 ng/mL or with MRI scans suggesting prostate cancer between January 2015 and August 2017.
|
30964117 |
2019 |